Page 2 - Nasdaq Grph News Today

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 EPS estimates for shares of Graphite Bio in a research report issued on Monday, March 20th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($0.13) for the quarter, up from […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2022 earnings estimates for Graphite Bio in a report issued on Thursday, September 15th. Cantor Fitzgerald analyst O. Brayer forecasts that the company will post earnings per share of ($1.45) for the year. Cantor Fitzgerald currently has a “Overweight” rating […]

Graphite Bio (NASDAQ:GRPH – Get Rating) and Cellectis (NASDAQ:CLLS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Graphite Bio and Cellectis’ […]

Graphite Bio (NASDAQ:GRPH – Get Rating) is one of 262 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Graphite Bio to related companies based on the strength of its institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Valuation and Earnings This […]

Graphite Bio (NASDAQ:GRPH – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) has been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,580,000 shares, a decline of 36.0% from the March 31st total of 4,030,000 shares. Approximately 10.7% of the company’s shares are sold short. Based on an average […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,030,000 shares, a growth of 33.0% from the March 15th total of 3,030,000 shares. Based on an average daily volume of 296,200 shares, the […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) insider Phil Gutry purchased 5,000 shares of the stock in a transaction that occurred on Monday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $20,050.00. Following the completion of the acquisition, the insider now owns 299,941 shares […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) major shareholder Biocapital L.P. Samsara acquired 74,464 shares of the firm’s stock in a transaction that occurred on Monday, April 11th. The stock was acquired at an average price of $4.07 per share, with a total value of $303,068.48. Following the completion of the acquisition, the insider now […]